464913-11-9Relevant articles and documents
Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists
Merritt, J. Robert,Rokosz, Laura L.,Nelson Jr., Kingsley H.,Kaiser, Bernd,Wang, Wei,Stauffer, Tara M.,Ozgur, Lynne E.,Schilling, Adriane,Li, Ge,Baldwin, John J.,Taveras, Arthur G.,Dwyer, Michael P.,Chao, Jianping
, p. 4107 - 4110 (2006)
A novel series of 3,4-diaminocyclobut-3-ene-1,2-diones was prepared and found to show potent inhibitory activity of CXCR2 binding and IL-8-mediated chemotaxis of a CXCR2-expressing cell line. Microsome stability and Caco2 studies were subsequently used to
Bicyclo[2.2.1]heptane containing: N, N ′-diarylsquaramide CXCR2 selective antagonists as anti-cancer metastasis agents
Che, Jin-Xin,Wang, Zhi-Long,Dong, Xiao-Wu,Hu, You-Hong,Xie, Xin,Hu, Yong-Zhou
, p. 11061 - 11069 (2018/03/26)
CXCR1 and CXCR2 are CXC chemokine receptors (CXCRs), corresponding to cytokines of the CXC chemokine family. CXCR2 was found to be 77% homologous to CXCR1. Antagonism of the chemokine receptor CXCR2 has been proposed as a new strategy for the treatment of
NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES
-
Paragraph 0102, (2014/10/16)
Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the tr